Analysed BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) News Sources
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16
07-04-2026
yahoo.com
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
01-04-2026
yahoo.com
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
25-03-2026
yahoo.com
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
17-03-2026
yahoo.com
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
13-03-2026
yahoo.com
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
10-03-2026
yahoo.com
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
03-03-2026
yahoo.com
What is the current price of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The current price of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is $3.35.
BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) since the previous trading day is $0.03.
BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) since the previous trading day is 0.9036%.
What is the most recent average sentiment score for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The most recent average sentiment score for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is 90 out of 100.
What is the most recent average sentiment for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)?
The most recent sentiment for BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ) is .
SEC-8K** Filing Available For BIOAFFINITY TECHNOLOGIES INC (BIAF:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.